The 90-kDa heat shock protein, HSP90, is an abundant molecular chaperone which functions in cellular homeostasis in prokaryotes and eukaryotes. It is well known that HSP90 plays a critical and indispensable role in regulating cell growth through modulations of various signal transduction pathways, but its roles in cell cycle control are not so well known. We transferred human HSP90 (wild-type or mutated types) expression vectors into NIH-3T3 cells in order to study certain functions of HSP90 in the cell cycle and cell growth under physiological conditions. We found that the exogenous expression of HSP90 (wild-type) induced a decrease in cell growth via retardation of the G1/S transition. The inhibition of cell growth was caused by reduced expressions of cyclin D3 and cyclin A mRNA and protein. On the other hand, no stable transfectants with the three types of mutated HSP90 were obtained. Unexpectedly, exogenous HSP90 expression impaired the heat shock response by inhibiting both heat shock transcription factor 1(HSF1) activation and transportation of HSF1 into the nucleus. The HSF1 function was disrupted by the direct association between HSF1 and exogenous HSP90, which was present as a monomer. These results reveal important roles of HSP90 in cell cycle control and in the stress response of nontransformed cells. © 2002 Elsevier Science (USA)
INTRODUCTION
The 90-kDa heat shock protein (HSP90) is one of the most abundant cytosolic proteins in eukaryotes, amounting to ϳ1% of soluble proteins even in the absence of stress [1, 2] . HSP90 plays an essential and indispensable role in cell growth [3] . HSP90 is different from other chaperones in the de novo folding of nascent polypeptides [2, 4] . It is well known that HSP90 functions as a chaperone involved in the maturation of signal tranduction proteins [1, 5] . For example, numerous molecules involved in cell proliferation, such as v-Src [6] , Raf [7, 8] , Akt [9] , MyoD [10] , SV40 [11] , and HSF1 [12] , combine directly with HSP90. The 25-kDa N-terminal domain of HSP90 has recently been crystallized and found to contain binding sites for adenosine 5Ј-triphosphate (ATP) and geldanamycin (GA), an antitumor drug which inhibits HSP90 functions [13] [14] [15] .
Mammalian HSP90 has two isoforms: the ␣ isoform, a protein induced by stress, and a ␤ isoform which is constitutively expressed. HSP90 forms ␣/␣ and ␤/␤ homodimers which are necessary for its appropriate functioning, and only a part of HSP90␤ but not HSP90␣ exists as monomers [16, 17] . In previous studies, we found that the overexpression of HSP90␤ but not HSP90␣ impaired differentiation of human embryonal carcinoma (EC) cells into trophoectodermal cells [18] . Recently, Voss et al. reported that HSP90␤ has a key role in placental development, which cannot be compensated by endogenous HSP90␣ alone [19] . This result confirms that, in certain cell types, HSP90␤ plays roles different from those of HSP90␣ during mammalian development.
HSP90 has certain indispensible functions in maintaining cellular homeostasis. It has been found that the deletion of HSP90 is lethal for yeast and that some mutations of Drosophila HSP83, a homologue of mammalian HSP90, induced a similar defect in eye development due to the lack of sevenless tyrosine kinase [20] . Recently, Rutherford et al. have demonstrated a novel role of HSP90, which links the cellular functions of HSP90 to evolutionary changes in developmental processes [21] . Their results revealed that abundant HSP90, even under physiological conditions, functions as a "buffer" to keep the cellular machinery working well and protects against various stresses, which often induce sudden increases in the numbers of nonnative proteins.
Herein, we investigated whether the overexpression of HSP90 in NIH-3T3 cells has an effect on cell viabil-
FIG. 1. Gene transfer of human HSP90 expression vectors into NIH-3T3 cells. (A)
The schema of human HSP90␤ with myc-tag expression vector. Human HSP90␤ cDNA is driven by the SR␣ promoter, which is composed of simian virus 40 early promoter and the R-U5 segment of the human T-cell leukemia virus type 1 long terminal repeat. The HSP90␤ coding region (gray square) was inserted downstream from the myc-tag sequence (black square) in frame. This vector has a neomycin resistance gene (neo r ) with an SV40 promotor. The positions of three point mutations in the N-terminal (M1), middle domain (M2), or C-terminal (M3) are indicated by arrows. (B) The expression of exogenous human HSP90 proteins with the myc-tag. After selection with G418 (500 g/ml), cells were subcloned. Total cell lysates were extracted and Western blotting using anti-myc-tag antibody (clone 9E10) was done. Seven clones with exogenous HSP90 expression were obtained (clone numbers 1, 2, 7, 12, 13, 15, and 19) . (C) Increased expression of total HSP90 in HSP90 clones. Twenty micrograms of protein was applied in each lane for SDS-PAGE and Western blotting was performed using anti-HSP90 monoclonal antibody (clone 3B6, which recognizes both human and murine HSP90, top panel) or anti-HSC70 monoclonal antibody (bottom panel). The expression of total HSP90 in two HSP90 clones was significantly increased compared with that in the myc-tag clone. On the other hand, HSC70 expressions in the three clones were similar. Denmark) and analyzed using a confocal laser microscope (Carl Zeiss, LSM 510, Heidelberg, Germany).
Polyacrylamide gel electrophoresis and Western blot analysis. For Western blot analysis of total protein, lysis buffer [10 mM Tris, pH 8.0, 150 mM NaCl, 0.1% SDS, 1 mM EDTA, 1% NP-40, and complete protease inhibitor cocktail (Roche, Mannheim, Germany)] was used. The protein concentration was quantified using a protein assay kit (Bio-Rad) according to the manufacturer's instructions. The purified monomeric human HSP90 (StressGen, Victoria, Canada, purified from HeLa cells) was used as a positive control for Western blot analysis. Equal amounts of protein extracts (20 g) were fractionated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) using 4 -12% gradient polyacrylamide gels (Novex). After electrophoresis, the proteins were transferred onto PVDF (BioRad) or nitrocellulose membranes (Amersham Pharmacia Biotech, Bunkinghamshire, UK) and blocked with 5% skim milk in TBST (20 mM Tris/HCl, pH 7.5, 137 mM NaCl, 0.1% Tween 20) for 1 h at room temperature. The membranes were incubated with primary antibodies (diluted in TBST with 5% skim milk) for 1 h at room temperature. Mouse anti-c-myc-tag (monoclonal (9E10) or polyclonal antibody, Santa Cruz, CA), mouse anti-HSP90 (clone: 3B6, Affinity Bioreagents, Golden, CO), mouse anti-HSP90 (clone: AC88, StressGen), mouse anti-HSP70, mouse anti-HSC70 (StressGen), and mouse antiglyceraldehyde-3-phosphate dehydrogenase (Advanced ImmuoChemical, Long Beach, CA) monoclonal antibody were used as primary antibodies. After washing with TBST, the membranes were incubated with the appropriate secondary antibody for 1 h at room temperature and visualized using an ECL kit (Amersham Pharmacia Biotech) according to the manufacturer's instructions. Nondenaturing PAGE for analysis of HSP90 isoforms was conducted according to Minami et al. [17] using 4 -12% gradient polyacrylamide gels without SDS (Novex).
Electrophoretic mobility shift assay. The electrophoretic mobility shift assay was performed as described previously with a self-complementary ideal heat shock element (HSE) oligonucleotide (5Ј-CTA GAA GCT TCT AGA AGC TTC TAG-3Ј), which contains four perfect inverted NGAAN repeats when annealed [24, 25] . To prepare nuclear protein extracts, first, buffer A [10 mM HEPES-KOH, pH 7.9, 10 mM NaCl, 0.1 mM EDTA, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM DTT, 4 g/ml of aprotinin, 4 g/ml of leupeptin, 0.5 mM sodium orthovanadate] was added to cell pellets and the cell suspension was incubated on ice for 15 min with occasional vortexing. Nuclei, confirmed by light microscopic observation, were collected and resuspended in buffer C [20 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 25% glycerol, 1 mM PMSF, 1 mM DTT, 4 g/ml of aprotinin, 4 g/ml of leupeptin, 0.5 mM sodium orthovanadate] and incubated on ice for 30 min. After removing the nuclear debris by centrifugation for 10 min at 4°C, the protein concentration was quantified using the protein assay kit (Bio-Rad). Lysates were mixed with 0.1 ng of [␣-
32 P]ATP-labeled HSE oligonucleotide and 0.5 g of poly(dI-dC) in 25 l of binding buffer (10 mM Tris, pH 7.8, 50 mM NaCl, 1 mM EDTA, 0.5 mM dithiothreitol, and 5% glycerol). Binding reactions were incubated for 20 min at 25°C and directly loaded onto a 4% polyacrylamide gel in 6.7 mM Tris (pH 7.5), 1 mM EDTA, and 3.3 mM sodium acetate. Gels were run at room temperature for 2.5 h at 120 V, dried, and analyzed with an image analyzer (Storm). In reactions using competitor oligonucleotides, a 50-mol excess of unlabeled competitor oligonucleotides was used. In antibody supershift experiments, 1 g of rabbit anti-HSF1 polyclonal antibody (Affinity Bioreagents) was preincubated with the nuclear extract for 15 min on ice before adding the 32 P-labeled probe.
Immunolocalization. Cells were cultured in two-well chamber slides (NUNC, Naperville, IL). The cells were rinsed with PBS and fixed in 4% paraformaldehyde for 15 min at room temperature. The slides were washed three times with PBS and permeabilized for 10 min at room temperature with PBS containing 0.2% Tween 20. After blocking with 3% BSA and 0.2% Tween 20 in PBS for 1 h at room temperature, slides were incubated in the presence of primary antibodies (rabbit anti-HSF1 polyclonal antibody (Affinity Bioreagents), mouse anti-HSP90 monoclonal antibody (clone 3B6, Affinity Bioreagents), and mouse anti-c-myc antibody (clone 9E10, Santa Cruz)) for 1 h at room temperature and incubated with secondary antibodies (FITC-conjugated rabbit antimouse antibody (1:50; Dako) and Cy5-conjugated goat antirabbit antibody (1:500; Amersham Pharmacia Biotech)) for 1 h. All antibodies were diluted in 3% BSA and 0.2% Tween 20 in PBS. The slides were washed three times in PBS containg 0.2% Tween 20 and then rinsed once in PBS and mounted with fluorescent mount medium (Dako). The immunolocalization was observed using a confocal laser microscope (Carl Zeiss, LSM 510).
Immunoprecipitation. Immunoprecipitation was performed to investigate the interaction between exogenous HSP90 and HSF1. Cells were treated with lysis buffer containing 50 mM MOPS (pH 7.3), 25 mM ␤-glycerol phosphate, 2 mM EDTA, and a complete protease inhibitor cocktail set (Roche). The lysates were microcentrifuged at 4°C for 30 min. Eight hundred micrograms of protein from each sample was precleared with rec-protein G-Sepharose 4B (ZYMED, San Francisco, CA) at 4°C for 1 h, and then 5 g of rat anti-HSF1 monoclonal antibody (Ab-4, NeoMarkers, Fremont, CA) was added. After incubation at 4°C for 4 h, 40 l of protein G-Sepharose 4B beads were added and the mixture was incubated with rotation at 4°C for 4 h. Immunoprecipitates were then washed five times with lysis buffer and the protein G-antibody-antigen complex was then applied to SDS-PAGE and analyzed by Western blotting with rabbit anti-HSF1 polyclonal antibody (Affinity Bioreagents), HSP90 (clone 3B6), and myc-tag (clone 9E10) antibodies. (40 g) of myc-tag or HSP90 clones were applied to 8% native Tris-glycine PAGE. Western blotting with a mouse anti-HSP90 antibody (clone AC88, left) and a rabbit anti-myc-tag polyclonal antibody (right) was then performed. Purified human monomeric HSP90 (StressGen) was used as a standard. Neither the homodimer of exogenous HSP90␤ nor the heterodimer of exogenous HSP90␤ and endogenous murine HSP90 was found. Exogeneous HSP90 was present only as a monomer.
ice-cold PBS, treated cells were lysed in RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, and complete protease inhibitor cocktail) on ice for 30 min and centrifuged at 15,000 rpm at 4°C for 30 min. Supernatants were immunoprecipitated with 5 g of rabbit anti-cyclin A or rabbit anticyclin D3 polyclonal antibodies (Santa Cruz), as described above.
Immunoprecipitates were applied to 4 -12% SDS-gradient polyacrylamide gels, dried, exposed to X-ray film, and quantitated using NIH imaging.
Statistical analysis. All results were evaluated using Student's t-test-based or two-tailed paired t-test-based statistics. Experiments were performed at least three times each.
RESULTS

Gene Transfers of Human HSP90 Expression Vectors into NIH-3T3 Cells
The human HSP90␤ expression vector was used for overexpression experiments using murine NIH-3T3 cells. Human HSP90 may function physiologically in murine cells in a manner like murine HSP90 because the HSP90 gene and protein are highly conserved between species. Human HSP90␤ (wild-type or one of three mutated types) cDNA or the myc-tag sequence driven by the SR␣ promoter was transferred into NIH-3T3 cells. The construction of vectors is shown in Fig.  1A . After selection with G418 for 10 -14 days, we screened stable clones with human HSP90 expression using Western blotting by anti-myc-tag antibody (9E10). As shown in Fig. 1B , approximately 90-kDa bands were observed in HSP90-transfected clones, while no corresponding band was observed in the myctag-transfected cells (a control). We obtained seven clones with human HSP90 (wild-type) expression (HSP90 clones). Six clones with the SR␣ myc-tag vector were established using the same method as that for control clones, which were named the myc-tag clones. We attempted to obtain clones transfected with the human HSP90 gene containing a point mutation in the N-terminal (M1), middle domain (M2), or C-terminal (M3) (Fig. 1A) . However, no stable clones with any one of the mutated HSP90 clones (M1-3) were obtained, despite repeated attempts.
Two clones transfected with wild-type HSP90 vector (HSP90 clones 2 and 15) were used in all experiments, as follows, and one clone transfected with the myc-tag vector (myc-tag clone) was used as a negative control. Total amounts of HSP90 expression were observed using Western blotting with a mouse anti-HSP90 antibody (3B6). The overall HSP90 expression in HSP90 clones 2 and 15 was significantly increased compared with myc-tag cells but the additive expression of exogenous HSP90 was not high (Fig. 1C) . The expression of HSC 70, which was expressed constitutively, showed no differences in any of the clones. The HSP90 expression in nontransfected NIH-3T3 cells (parent cells) is similar to one in the myc-tag clones (data not shown).
It has been reported that most cellular HSP90 exists as ␣/␣ and ␤/␤ homodimers and a part of HSP90␤ exists as monomers [16, 17] . We investigated whether exogenous HSP90 exists as a dimer or a monomer by native PAGE and Western blotting using rabbit antic-myc polyclonal and mouse anti-HSP90 monoclonal antibody (AC88). The HSP90 purified from HeLa cells, as a positive control, was revealed as a monomer. We found the exogenous HSP90␤ to exist almost as a monomer (Fig. 2) . Neither the homodimer of exogenous HSP90␤ nor the heterodimer of exogenous HSP90␤ with endogenous murine HSP90 was found (Fig. 2) . Minami et al. reported that the monomeric form of HSP90 in murine L5178Y lymphoma cells consisted mainly of the ␤ but not the ␣ isoform [17] . Nemoto et al. concluded that both of the HSP90 isoforms predominantly exist as oligomeric forms in rat liver cytosol but that they artificially dissociate into smaller forms when subjected to native PAGE by some investigations using the novel two-dimensional double native PAGE method [26] . The proportion of monomeric HSP90 in NIH-3T3 cells was higher than the proportion of monomer, which was reported by Minami et al., in the L5178Y lymphoma cells (Fig. 2) . This discrepancy may be explained by not only the condition of native PAGE but also the difference of cell type.
We tested the localization of exogenous myc-tagged HSP90 using a confocal laser microscope with antimyc-tag antibody (9E10). As shown in Fig. 3 , the exogenous HSP90 existed mostly in the cytoplasm in HSP90 clones 2 and 15, while no staining was detected in the myc-tag clone.
Cell Growth Was Retarded by Exogenous HSP90 Expression
The cell growth rate of HSP90 clones was significantly though not dramatically retarded compared with that of the myc-tag clone at 48 h after seeding (Fig. 4A) . The optical densities of HSP90 clones 2 and 15 in the MTT assay were both under 60% of that of the myc-tag clone (Fig. 4B) . These results show that the exogenous expression of HSP90 significantly inhibits cell proliferation.
The Cell Cycle Was Delayed by Exogenous HSP90 Expression
We investigated whether the retarded cell growth due to exogenous HSP90 expression was attributable to cell cycle disruption. First, the cell cycle profile was observed using PI staining and flow cytometry. The proportion of HSP90 clone cells in G1 phase was slightly increased compared with that of the myc-tag clone (data not shown). In order to clarify the cell cycle states of HSP90 clones, cells were synchronized at G1 phase by serum deprivation and then restarted by the addition of complete medium. As shown in Fig. 5A , the delay in the transition from G1 phase to S phase was observed at 13 h after restarting the cell cycle in HSP90 clone 15 cells, while the G1/S transition was finished at the same time (13 h) in myc-tag cells. The cell cycle delay persisted until 16 h after restarting the cell cycle. The endogenous or exogenous HSP90 expression in the synchronized cells (both HSP90 clones and a myc-tag clone) was estimated by Western blotting using anti-myc-tag antibody (9E10) or anti-HSP90 antibody (3B6). As a result, both the endogenous and exogenous expressions of HSP90 were not altered before or after the synchronization (data not shown).
The coordination of cyclins and cyclin-dependent kinases (CDKs) is essential for accurate cell cycle progression. The transition from G1 to S phase is mainly controlled by G1 cyclins and CDK2, 4, 6 complexes [27, 28] . In order to investigate whether altered expressions of cyclins is involved in retardation of the cell cycle in HSP90 clones, we performed RNase protection assays for cell cycle regulators. As shown in Fig. 5B , the mRNAs of cyclin D3 and cyclin A in HSP90 clones 2 and 15 were both significantly reduced compared with that of the myc-tag clone. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was detected at the same level in all clones. We investigated the expressions of cyclin D3 and cyclin A proteins by Western blotting. Although the expressions of these proteins in whole cell lysates of HSP90 clones were slightly decreased, nuclear cyclin D3 and cyclin A were significantly decreased compared with the myc-tag clone (data not shown). The synthesis of cyclin D3 and cyclin A protein was monitored by metabolic labeling using [
35 S]methionine. Figure 5C shows the quantification of newly synthesized cyclin D3 and cyclin A proteins in HSP90 clones and the myc-tag clone. The newly synthesized cyclin D3 and cyclin A in HSP90 clones 2 and 15 were significantly reduced compared with that in the myc-tag clone. However, it was shown that the cyclin D3 or cyclin A protein didn't interact with the endogenous and exogenous HSP90 protein by pulldown assay (Western blotting with anti-myc-tag antibody or anti-HSP90 antibody after immunoprecipitation with anti-cyclin D3 or A antibody) (data not shown). These results suggest that inhibited cyclin D3 and cyclin A nuclear transportation and decreased expressions of cyclin D3 and cyclin A are responsible for the cell cycle retardation in HSP90 clones.
On the other hand, it was revealed that the CDK4 associated with the exogenous human HSP90 in HSP90 clones by the pulldown assay (Western blotting with anti-myc-tag antibody after the immunoprecipitation with anti-CDK4 antibody)(data not shown). It was suggested that the altered stabilization and/or translocation of CDK4 by the interaction of CDK4 with exogenous HSP90 in the presence of CDC37 caused cell cycle retardation in HSP90 clones.
Altered Heat Shock Response by Exogenous HSP90 Expression
The HSPs induced by stresses maintain cell viability via the protection of various forms of cellular machinery. Thus, we observed the heat shock response in HSP90 clones. Cell death induced by heat treatment (43°or 45°C, 1 h) was analyzed by PI staining, flow cytometry, and the TUNEL method. Unexpectedly, HSP90 clones 2 and 15 were both more sensitive to heat shock than the myc-tag clone. As shown in Fig.  6A , 24.6% (HSP90 clone 2) and 9.0% (HSP90 clone 15) of cells died with heat treatment, whereas only 4.9% of myc-tag clone cells were dead at the same time. Furthermore the TUNEL assay for detection of apoptotic cells was done. As a result, an increased number of apoptotic cell in HSP90 clones 2 and 15 was observed compared to that in the myc-tag cells (Fig. 6B) .
HSF1 Activation and Induction of HSP70 Were Impaired by Exogenous HSP90
HSF1 is an essential molecule for the induction of heat shock proteins in response to stresses. On the other hand, HSF1 is constutively stabilized by HSP90 [12] . The activation of HSF1 by heat treatment in HSP90 clones was tested using an electrophoretic mobility shift assay. As shown in Fig. 7A , HSF1/HSE complexes were observed in both HSP90 clones and the myc-tag clone after heat treatment, but the amount of HSF1/HSE complexes in the myc-tag clone was significantly greater than that in the HSP90 clone 15. The specificity of the HSF1 motif was confirmed by the addition of competitive non-radiolabeled probes. Furthermore, the addition of rabbit anti-HSF1 antibody suppressed the mobility of the HSF1/HSE complex. This result showed activition of HSF1 by heat treatment in the HSP90 clone to be impaired by exogeneous HSP90 expression.
To confirm these results, the induction of HSP70 after heat treatment (43°C, 1 h) was analyzed using Western blotting. As shown in Fig. 7B , the induction of HSP70 in the myc-tag clone was detectable at 1 h after heat treatment, whereas no induction of HSP70 in either HSP90 clones 2 or 15 was observed. The inhibition of HSP70 induction in HSP90 clones after heat treatment is consistent with the HSF1 inactivation in HSP90 clones observed by electrophoretic mobility shift assay. On the other hand, the expression of HSC70 and HSP70 in HSP90 clone 2 or 15 at physiological temperature (37°C) didn't differ from that in the myc-tag clone (Fig. 1B and data not shown) .
Immunolocalization of HSF1 and HSP90
In order to observe HSF1 and HSP90 localization before and after heat treatment, cells were dualstained with anti-HSF1 and anti-HSP90 antibodies and analyzed by confocal laser microscopy. As shown in Fig. 8, HSF1 was diffusely distributed in both the cytoplasm and the nucleus before heat treatment. In myc-tag cells, HSF1 immediately entered the nucleus and was diffusely distributed in the nucleus after heat treatment (43°C, 1 h), while HSF1 in HSP90 clones was located in the cytoplasm and around the nucleus after heat treatment. The localization of exogenous HSP90 after heat treatment was also detected using 
FIG. 6. Increased sensitivity to heat shock by exogenous HSP90 expression. (A)
The myc-tag clone and two HSP90 clones (clones 2 and 15) were heated (43°C, 1 h), and cell death was then measured using propidium iodide without fixation staining and flow cytometry. HSP90 clones 2 and 15 were both more sensitive to heat shock than the myc-tag clone; 24.6% (HSP90 clone 2) and 9.0% (HSP90 clone 15) of cells were dead, while only 4.9% of myc-tag clone cells were dead. (B) The myc-tag clone and two HSP90 clones (clones 2 and 15) were heated (45°C, 1 h), and apoptotic cells were then detected using the TUNEL method and confocal laser microscopy. Cells were fixed, reacted with TdT and FITC-conjugated dUTP (green), and stained with propidium iodide (red). HSP90 clones 2 and 15 were both more sensitive to heat shock than the myc-tag clone; 47.9% (HSP90 clone 2) and 38.8% (HSP90 clone 15) of cells were apoptotic, while 12.4% of myc-tag clone cells were apoptotic. The data are presented as mean values; error bars represent the SEM.
FIG. 7.
Inhibition of HSF1 activation by HSP90 overexpression. (A) HSF1 activitation in an HSP90 clone was impaired (electrophoretic mobility shift assay). Five micrograms of nuclear extracts from myc-tag or HSP90 clone 15, before or after heat treatment (43°C, 1 h), was incubated with the labeled probe and analyzed using an electrophoretic mobility shift assay. The specificity of DNA binding was verified by the addition of a competitor (unlabeled heat shock element, HSE, oligonucleotide). The supershift experiment was performed by adding anti-HSF1 antibody. HSF1/HSE complexes were observed in both HSP90 clones and the myc-tag clone after heat treatment, but the amount of HSF1/HSE complex in the myc-tag clone was significantly greater than that in the HSP90 clone 15. (B) Induction of HSP70 was impaired by exogenous HSP90 expression. Western blotting with murine anti-HSP70 and anti-GAPDH monoclonal antibodies was performed. The induction of HSP70 was detectable in the myc-tag clone at 1 h after heat treatment, whereas no induction of HSP70 was observed in either HSP90 clone 2 or clone 15. GAPDH expressions (as a control) were similar in all clones.
anti-myc-tag antibody, as shown in Fig. 8 . The exogenous HSP90 was diffusely present in the cytoplasm before (see Fig. 3 ) and after heat treatment. The images combining HSF1 and HSP90 showed HSF1 to be present around the nucleus and colocalized with HSP90 in HSP90 clones after heat treatment, whereas HSF1 in myc-tag cells entered the nucleus, showing virtually no colocalization with HSP90.
HSF1 Associated with Exogenous HSP90
Finally, we tested whether HSF1 interacted with exogenous HSP90 by pulldown assay (immunoprecipitation of HSF1 and Western blotting with anti-HSP90 or myc-tag antibody). As shown in Fig. 9 , HSF1 associated with exogeneous HSP90 in both HSP90 clones and the myc-tag clone. In addition, Western blotting using anti-myc-tag Ab revealed exogenous HSP90 to also be apparently associated with HSF1. These results showed that not only endogenous murine HSP90 associated with HSF1, but also exogenous HSP90 associated with HSF1 in HSP90 clones. The interaction of HSF1 and exogenous HSP90 may account for impairment of the heat shock response via the inhibition of both HSF1 activation and translocation of HSF1 into the nucleus.
DISCUSSION
The expression of exogenous human HSP90␤, which exists as a monomer in the cytoplasm of NIH-3T3 cells, induced significant though not dramatic inhibition of cell growth via retardation of the G1/S transition. Our results demonstrated this retardation of the cell cycle to be attributable to suppressed expression of cyclin D3 and cyclin A mRNAs and decreased cyclin D3 and cyclin A protein synthesis. Normal cellular replication is governed in part by periodic transcription of the cyclin genes, whose protein products associate with and positively regulate cyclin-dependent kinases. As the concentration of CDKs is fairly constant during the cell cycle, their activities are determined by the availability of different cyclins. D type cyclins (D1, D2, and D3) identified in the context of a delayed early response to growth factor stimulation are differentially, and in combination, expressed in mammalian cells [27, 29] . They form complexes with CDK2, 4, and 6 to control the transition from G1 to S phase. Studies on the role of cyclin D3 have implicated this protein in regulating cell fate, including proliferation, apoptosis, and differentiation [30] . Cyclin A, a critical regulator of the cell cycle at both the G1-S junction and during the G2-M transition [31, 32] , accumulates at the G1/S phase transition and persists through the S phase, promoting cell cycle progression by associating with and stimulating cyclin-dependent kinases CDC2 and CDK2. Therefore, reduced cyclin D3 and cyclin A protein in HSP90 clones may be responsible for the decreases in CDK/cyclin complexes and for the impaired G1-S transition through the interruption of retinoblastoma protein phosphorylation in mid to late G1 phase.
Previous studies have implied that HSP90 may function in cell cycle control [33] [34] [35] [36] , though the details of the underlying molecular mechanism are unknown.
Stepanova et al. reported that HSP90 and CDC37 contribute to the stablization of CDK4, which has important roles in the G1-S transition [37] . CDK4 is released from the HSP90/CDC37 complex and translocates into the nucleus after assembly with cyclin D. Recently Taules et al. reported that HSP90 interacts with CDK4 and that calmodulin inhibition induced CDK4 and cyclin D translocation to the cytoplasm point to HSP90 as a good candidate for being the calmodulin binding protein involved in the nuclear accumulation of CDK4 and cyclin D [38] . The cell cycle retardation in HSP90-overexpressed NIH-3T3 cells may be caused by the altered translocation of CDK4 and cyclin D. We detected the CDK4/exogenous HSP90 complex in HSP90 clones using the pulldown assay (data not shown). Therefore, the interaction between CDK4 and exogenous HSP90 may also contribute to impairment of the G1/S transition via the stablization of CDK4 and/or the inhibition of translocation of CDK4 and cyclin D.
How did the overexpression of HSP90 reduce cyclin D3 and cyclin A expressions? We were unable to observe any associations between HSP90 and cyclin D3 or cyclin A proteins (data not shown). Therefore, the reduced cyclin D3 and cyclin A expressions in HSP90 clones may be an indirect consequence of HSP90. Transcriptional control of cyclin gene expression is the most decisive factor determining the total amount of synthesized cyclins. The RNase protection assay and metabolic labeling experiment results suggest reduced cyclin D3 and cyclin A expressions to be caused at the transcriptional or translational level. However, the mechanism by which HSP90 interferes with the transcription or translation of cyclin D3 and cyclin A is unknown. D type cyclin acts as a growth factor sensor, and the synthesis of cyclin D is highly growth factor dependent. HSP90 associates with various molecules involved in signal tranduction from certain growth factors. These "clients" are stabilized and their activities may be inhibited by overexpression of HSP90. As a result, decreased cyclin D3 and cyclin A synthesis may occur through impairment of the signal transduction pathway, which was activated by growth factors in culture serum. On the other hand, cyclins are labile and disintegrate, depending on the cell cycle phase, via the ubiquitin-proteasome pathway [39, 40] . Since HSP90 overexpression may inhibit proteasome-mediated proteolysis, total amounts of cyclin D3 and cyclin A in HSP90 clones decreased slightly compared with newly synthesized cyclin D3 and cyclin A proteins [41] .
We attempted to transfer three types of mutated HSP90 vector into NIH-3T3 cells, but no clones with mutant HSP90 (M1-3) were obtained. M1, M2, and M3 of human HSP90␤ correspond to E1D, E6D, and E3A of Drosophila HSP83, a homologue of human HSP90, found by Rubin et al., respectively [20] . Drosophila with a homozygous mutation in HSP83 or CDC37 has a sevenless phenotype of the eye. Rutherford et al. demonstrated that these heterozygous mutations of HSP83 cause various developmental defects [21] . The M1 has a point mutation in the N-terminal, which is important for binding to ATP [13, 42] . M2 has a point mutation in the middle domain, which has a highly charged connecting hinge region with a KEKE motif and nuclear localization signal. M3 has a point mutation in the C-terminal, which is involved in formation of homodimer and ATPase activity [43] . Exogenous expression of these mutant HSP90s in NIH-3T3 cells may disrupt various important functions of HSP90 in cell growth and/or surrival, despite the expression of endogenous normal murine HSP90. These "dominant negative" functions of mutated HSP90s may be explained by the disruption of formation of various complexes, such as with the cytoskeleton (including filamentous actin [44] and tubulin), and/or the centrosomal machinery [45] .
It is well known that pretreatment with mild, i.e., nonlethal, heat enhances resistance to a subsequent lethal heat shock. This phenomenon represents socalled "acquired thermotolerance" [46, 47] . However, in our experiments, the overexpression of HSP90 increased sensitivity to heat treatment compared with the myc-tag clone. This result suggests that constitutive expression of exogenous HSP90 driven by the SR␣ promotor is different from the HSPs induction in acquired thermotolerance. In order to identify the underlying mechanism, we focused on the relationship of HSP90 with heat shock transcription factor 1. HSF1 is a member of the HSF family, which is ubiquitously expressed and is the most important regulator of stress responses. HSF1 functions in the induction of HSPs in response to heat treatment as well as chemical and pathophysiological stresses, such as ischemia or irradiation, in eukaryotes [48] . Under physiological conditions, HSF1 exists as an inactive monomer, which is negatively regulated by its own C-terminal hydrophobic repeat domain [49] , HSP90 [12] , and HSP70 or HSC70 repressor complexes [50] . In response to physiological stress, HSF monomers trimerize, translocate into nuclei, and bind within the major groove of DNA at conserved nGAAn repeats and activate target HSP genes [51] . Recently, HSP90 was shown to be a main regulator of HSF1 under various stressed conditions [52] . We have shown herein that increased sensitivity to heat treatment in the HSP90 clone is attributable to inhibition of HSF1 activation and translocation to nuclei via direct association of exogenous HSP90 with HSF1. This observation was further confirmed by the suppression of HSP70 induction in HSP90 clones after heat treatment.
Recently, it was reported that HSF1 orchestrates some critical physiological events during extraembryonic development under nonstressed conditions, based on an analysis using HSF1 -/-mice [53] . Furthermore, Voss et al. found that HSP90␤ has a key role in placental development, which cannot be compensated for by endogenous HSP90␣ alone [19] . In previous studies, we found that HSP90 showed remarkably high expression in undifferentiated human EC cells, which were subsequently significantly down-regulated during in vitro trophoectodermal differentiation, following retinoic acid (RA) or heat treatment [54, 18] . Surprisingly, heat shock treatment also triggered the down-regulation of HSP90 within 48 h. This down-regulation of HSP90 by heat treatment was shifted to an up-regulation pattern after cellular differentiation in response to RA treatment. We transfected human EC cells with the HSP90 expression vector. As a result, RA-induced differentiation of EC cells into a neural cell lineage was inhibited by overexpression of the HSP90␣ or ␤ isoform. On the other hand, the overexpression of HSP90␤ alone impaired cellular differentiation into trophoectoderm. These lines of evidence suggest that a specific isoform of HSP90 is involved in certain stages of development and that HSF1 is used as a controller in early development but not in the stress response.
Reportedly, HSP70 and HSP90 negatively regulate apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome [55] [56] [57] . Our observation that the overexpression of HSP90 induced an increase in apoptotic cells after heat treatment may be explained by inhibited HSP70 induction via the disruption of HSF1 functions. However, whether exogenous HSP90 expression influences apoptosomes or caspases remains unknown.
Finally, it is very important in the development of antitumor drugs that HSP90 is involved in the cell cycle. GA binds to the ATP binding site of the HSP90 N-terminal and inhibits ATPase activity [52, 58] . One of the geldanamycin derivatives, 17-allylamino-17-demethoxygeldanamycin (17AAG) has recently entered Phase I trials in cancer patients [59] . Clarke et al. showed that HSP70 genes were consistently up-regulated in colorectal cancer cell lines, whereas HSP90␤ was either up-regulated or down-regulated, depending on the cell line, in a fashion that appeared to correlate with cellular sensitivity to GA [59] . It has been shown that exposure to GA or its derivatives induces HSP70 and HSP90 expression through activation of HSF1 [52, 60] . Our results may show the possibility of developing a novel drug, which impairs the cell cycle, especially the G1/S transition, via the altered interaction between HSP90 and client proteins, for example, CDK4 and HSF1.
